Increased life expectancy makes it even more important for us to pursue our vocation: finding effective therapeutic solutions to cure patients or relieve their suffering and offer value to the community.
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
Endocrinology is one of Ipsen's key specialty care pillars, focusing on endocrine oncology (neuroendocrine tumors or NET), pituitary pathologies (acromegaly), and growth disorders (growth hormone and IGF-1 deficiencies).
Ipsen is a key player in the treatment of movement disorders. The group is committed to improving the mobility, independence and quality of life of patients with these very disabling disorders. Ipsen’s consolidated expertise in the field of neurotoxins dates back over 25 years.
In primary care, Ipsen offers treatments for gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Ipsen has had a strong presence in international markets in this field for many years.